Mangini Siobhan Nolan - Mar 3, 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
Chief Financial Officer
Signature
/s/ Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Mar 3, 2022
Transactions value $
$0
Form type
4
Date filed
3/4/2022, 03:05 PM
Next filing
Jul 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +200K $0.00 200K Mar 3, 2022 Common Stock 200K $15.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.